Minimal Invasive Biopsy Results of ”Uncertain Malignant Potential” in Digital Mammography Screening: High Prevalence but also High Predictive Value for Malignancy

Zusammenfassung

Ziel: Aus der Abklärungsdiagnostik des digitalen Mammografie-Screenings wurden die Rate, das histologische Spektrum und der positive Vorhersagewert (PPV) hinsichtlich Malignität von Brustläsionen minimalinvasiver Biopsien „unklaren malignen Potenzials (B3)” untersucht. Material und Methoden: Konsekutive Untersuchungen von 37 178 Teilnehmerinnen einer digitalen Einheit des deutschen Screeningprogramms wurden eingeschlossen. Ergebnisse: Die B 3-Rate war 15,1 % (148 / 979). Es lagen folgende Häufigkeiten der B 3-Subtypen vor: atypische epitheliale Proliferationen vom duktalen Typ (AEPDT) 35,1 % (52 / 148), radiäre Narben (RS) 28,4 % (42 / 148), papilläre Läsionen (PAP) 20,3 % (30 / 148), Carcinoma lobulare in situ 8,8 % (13 / 148), flache epitheliale Atypien 5,4 % (8 / 148), mukozelenartige Läsionen 2,0 % (3 / 148). Der PPV für Malignität in der sekundären chirurgischen Exzision betrug insgesamt 0,28 (25 / 91); dabei ist der PPV 0,40 (19 / 47) für die AEPDT, 0,20 (5 / 25) für die RS, 0,08 (1 / 12) für PAP. Schlussfolgerung: Trotz einer höheren B 3-Rate von Brustläsionen mit „unklarem malignem Potenzial” minimalinvasiver Biopsien im digitalen Mammografie-Screening ist die Rate benigner chirurgischer Exzisionen im Vergleich zum analogen Screening nicht unverhältnismäßig erhöht. In Kombination mit einem konsequenten interdisziplinären Management resultiert eine erhöhte Brustkrebsentdeckungsrate pro Screeningteilnehmerin mit offener Biopsie.

Abstract

Purpose: To evaluate the rate, the histological spectrum and the positive predictive value (PPV) for malignancy of minimally invasive biopsies with ”uncertain malignant potential (B3)” in digital mammography screening. Methods and Materials: Consecutive data of 37 178 participants of one digital unit of the German screening program were included. Results: The B 3 rate was 15.1 % (148 / 979). The frequencies of lesion subtypes were as follows: atypical epithelial proliferation of ductal type (AEPDT) 35.1 % (52 / 148), radial scar (RS) 28.4 % (42 / 148), papillary lesions (PAP) 20.3 % (30 / 148), lobular carcinoma in situ 8.8 % (13 / 148), flat epithelial atypia 5.4 % (8 / 148), and mucocele-like lesions 2.0 % (3 / 148). The PPV for malignancy in surgical excisions was overall 0.28 (25 / 91); in detail 0.40 (19 / 47) for AEPDT, 0.20 (5 / 25) for RS, 0.08 (1 / 12) for PAP. Conclusion: Despite a higher B 3 rate of minimally invasive biopsies with ”uncertain malignant potential” in digital screening, the benign surgical biopsy rate is not disproportionally increased compared with analog screening programs. Together with defined management protocols, this results in an increased cancer detection rate per screening participant with surgical excision.

breast - biopsy - mammography screening - digital mammography - histology - predictive value

References

• 1 Del Turco M R, Mantellini P, Ciatto S et al. Full-field digital versus screen-film mammography: comparative accuracy in concurrent screening cohorts.  Am J Roentgenol. 2007;  189 860-866
• 2 Skaane P, Hofvind S, Skjennald A. Randomized trial of screen-film versus full-field digital mammography with soft-copy reading in population-based screening program: follow-up and final results of Oslo II study.  Radiology. 2007;  244 708-717
• 3 Vigeland E, Klaasen H, Klingen T A et al. Full-field digital mammography compared to screen film mammography in the prevalent round of a population-based screening programme: the Vestfold County Study.  Eur Radiol. 2008;  18 183-191
• 4 Weigel S, Decker T, Korsching E et al. Calcifications in Digital Mammographic Screening: Improvement of Early Detection of Invasive Breast Cancers?.  Radiology. 2010;  255 738-745
• 5 Perry N M, Broeders M, Wolf de C et al. European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis. Luxembourg: Office for Official Publications of the European Communities; 2006 4th edn
• 6 Hungermann D, Weigel S, Korsching E et al. Mikrokalkdiagnostik an minimal-invasiven Biopsien im Mammographie-Screening.  Pathologe. 2009;  30 31-35
• 7 Andreu F J, Saez A, Sentis M et al. Breast core biopsy reporting categories – An internal validation in a series of 3054 consecutive lesions.  The Breast. 2007;  16 94-101
• 8 Carder P J, Liston J C. Will the spectrum of lesions prompting a ”B3” breast core biopsy increase the benign biopsy rate?.  Journal of Clinical Pathology. 2003;  56 133-138
• 9 Houssami N, Ciatto S, Bilous M et al. Borderline breast core needle histology: predictive values for malignancy in lesions of uncertain malignant potential (B3).  British Journal of Cancer. 2007;  96 1253-1257
• 10 Lee A HS, Denley H E, Pinder S E et al. Excision biopsy findings of patients with breast needle core biopsies reported as suspicious of malignancy (B4) or lesion of uncertain malignant potential (B3).  Histopathology. 2003;  42 331-336
• 11 El-Sayed M E, Rakha E A, Reed J et al. Predictive value of needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening.  Histopathology. 2008;  53 650-657
• 12 Lieske B, Ravichandran D, Alvi A et al. Screen-detected breast lesions with an indeterminate (B3) core needle biopsy should be excised.  Eur J Surg Oncol. 2008;  34 1293-1298
• 13 Hayes B D, O’Doherty A, Quinn C M. Correlation of needle core biopsy with excision histology in screen-detected B 3 lesions: the Merrion Breast Screening Unit experience.  Journal of Clinical Pathology. 2009;  62 1136-1140
• 14 Weigel S, Batzler W, Decker T et al. Erste epidemiologische Analyse der Brustkrebsinzidenz und der Tumorcharakteristika nach Implementierung des populationsbezogenen digitalen Mammografie-Screening-Programms.  Fortschr Röntgenstr. 2009;  181 1144-1150
• 15 American College of Radiology (ACR) .Illustrated breast imaging reporting and data system (BI-RADS). Reston, VA: American College of Radiology; 1998 3rd edn
• 16 Wells C A, Amendoeira I, Apostolikas N. et al .Quality assurance guidelines for pathology. In: Perry N M, Broeders M, Wolf de C, eds. European guidelines for quality assurance in breast cancer screening and diagnosis. Luxembourg: Office for Official Publication of the European Communities; 2006: 219
• 17 Müller-Schimpfle M. Konsensustreffen der Kursleiter in der Mammadiagnostik am 5.5.2007 in Frankfurt am Main. Thema Mikrokalk.  Fortschr Röntgenstr. 2008;  180 66-68
• 18 Douglas-Jones A G, Denson J L, Cox A C et al. Radial scar lesions of the breast diagnosed by needle core biopsy – analysis of cases containing occult malignancy.  Journal of Clinical Pathology. 2007;  60 295-298
• 19 Linda A, Zuiani C, Bazzocchi M et al. Borderline breast lesions diagnosed at core needle biopsy: can magnetic resonance mammography rule out associated malignancy? Preliminary results based on 79 surgically excised lesions.  Breast. 2008;  17 125-131
• 20 Schell M J, Yankaskas B C, Ballard-Barbash R et al. Evidence-based Target Recall Rates for Screening Mammography.  Radiology. 2007;  243 681-689
• 21 Abdel-Fatah T M, Powe D G, Hodi Z et al. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family.  Am J Surg Pathol. 2008;  32 513-523